Skip to main content

RheumNow Podcast – Rheumatologist Salaries (12.21.18)

Dr. Jack Cush reviews the news from RheumNow for the week ending 12/21/18.

  1. Study from the UK BSRBR registry shows 34 cancers & 41 deaths in 709 pts. Risk of CA w/ TNFi was not increased (SIR 0.94; 95% CI 0.65,1.34) (but for 2 fold incr risk of nonmelanoma skin CA) & all-cause mortality rate was increased (SMR 1.56) from CV events https://t.co/6HSnw5SOF8   
  2. Clinical pain severity & disability in OA is higher amongst African Americans vs Whites. Metanalysis of 61 articles shows higher pain severity in AA using the WOMAC (0.57; 95%CI: 0.54, 0.61) & non-WOMAC studies (0.35; 95%CI: 0.23, 0.47). Journal of Pain. https://t.co/qLm2Pbw7pz   
  3. Check out Vinay Prasads @VPplenarysesh Plenary Session Podcast that discusses studies on Fish oils and MTX in cardiology - the CIRT NEJM study appears at 35:23 - interesting to hear non-Rheum views on this approach https://t.co/MQCWLYgEnD   
  4. Bing Bingham MD talking on immune related adverse events (MSK and autoimmune). Says these occur in 3-5% of cancer pts treated with Checkpoint inhibitors. Unofficial surveys show nearly 50% of Rheums have seen these referrals. #MARS #ARTHROS https://t.co/yZHMQjpMz8
  5. With irAEs arthralgias snd arthritis are common, but also can present as tendinitis tenosynovitis, dactylitis, PMR and most are seronegative https://t.co/WRvczdEsh9     
  6. 27yoF w/ chronic 4 mos b/l knee effusions (SF WBC=22K, -C/S), MRI synovitis only, Labs normal but with +ANA 1:160, neg Parvo, B27, RF, CCP, RPR, HCV/HBV, ESR and CRP. No resp to NSAIDs or IA steroids. DX?   
  7. Rheumatologist and Physician Salaries for 2018     
  8. Nailfold Videocapillaroscopy in Dermatomyositis 
  9. H2H: Ixekizumab vs. Adalimumab in Psoriatic Arthritis   
  10. Early Registration for RheumNow Live march 22-24, 2019 in Fort Worth, TX

 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has received compensation as an advisor or consultant on this subject